Skip to main content

Clinical Trials Using Nivolumab

Review the clinical trials studying nivolumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 186

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
Nivolumab in Combination with Trametinib with or without Dabrafenib for the Treatment of Newly Diagnosed, Progressive or Recurrent Low Grade or High Grade Childhood Gliomas
Status: Active
Location: 3 locations
Ex Vivo Expanded CD34+ Hematopoietic Stem Cells in Combination with Nivolumab for the Treatment of Recurrent, Progressive, or Refractory Pediatric High-grade Glioma
Status: Active
Location: 3 locations
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Status: Active
Location: 4 locations
Nivolumab and Relatlimab in Treating Patients with Locally Advanced or Metastatic Mismatch Repair Deficient Solid Tumors Resistant to Prior PD-L1 Therapy
Status: Active
Location: 2 locations
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Status: Active
Location: 2 locations
Axatilimab in Combination with Nivolumab for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 2 locations
Nivolumab for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients with Sub-optimal Response to Idecabtagene Vicleucel
Status: Active
Location: 2 locations
Immune Checkpoint Inhibition in Combination with Cryoablation for the Treatment of Patients Undergoing Surgery for Early Stage Triple-Negative Breast Cancer
Status: Active
Location: 2 locations
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
Daratumumab in Combination with KRAS Vaccine and Nivolumab in Treating Refractory Pancreatic Ductal Cancer and Advanced Refractory Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
Nivolumab in Combination with Axitinib for the Treatment of Advanced or Unresectable Mucosal Melanoma
Status: Active
Location: 2 locations
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
Status: Active
Location: 2 locations
XL092 with or without Nivolumab for the Treatment of Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: 2 locations
Cabozantinib, Ipilimumab, Nivolumab, and Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
Status: Active
Location: 2 locations
Study of DF1001 in Patients with Advanced Solid Tumors
Status: Active
Location: 3 locations
Degarelix with or without pTVG-AR and with or without Nivolumab for the Treatment of Prostate Cancer
Status: Active
Location: 2 locations
Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors
Status: Active
Location: 2 locations
Emavusertib in Combination with Combination Chemotherapy and Immunotherapy with or without Trastuzumab for the Treatment of Advanced Unresectable or Metastatic Gastric or Esophageal Cancer
Status: Active
Location: 2 locations
Immunosensitizing Radiation with Neoadjuvant Chemoimmunotherapy for the Treatment of Patients with Stage II-IIIC Borderline Resectable Non-Small Cell Lung Cancer, The NeoRADjuvant Trial
Status: Active
Location: 2 locations
Genetically Engineered Cells (Autologous Anti-HER2 CAR-CD28 T Cells) in Combination with Immune Checkpoint Inhibitors for the Treatment of Advanced Sarcoma
Status: Active
Location: 2 locations
A Vaccine (VSV-hIFNβ-NIS) with or without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Status: Active
Location: 2 locations
Implantable Microdevice for Evaluating Drug Responses in Patients with Head and Neck Cancers, the Window of Opportunity Study
Status: Active
Location: 2 locations
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania